Arbutus Biopharma Shares Are Trading Higher After the Company Presented Clinical Trial Data From Its Two HBV Assets.
Express News | Arbutus's Imdusiran Plus VTP-300 And Low-Dose Nivolumab Achieve HBsAg Loss And Seroconversion In CHBV Patients, New Phase 2a Data Reveal At EASL 2025
Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
Express News | Arbutus Biopharma To Present Key Hepatitis B Data, Including Late-Breaker, At EASL Congress 2025
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk
Arbutus Biopharma Faces Executive Changes Amid Legal Battle
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma's Strategic Restructuring and Legal Prospects Justify Buy Rating
Express News | Arbutus Biopharma Shares Are Trading Higher on Possible Continued Strength After the Company Reported a Year-over-year Increase in FY24 EPS Results on Thursday
Express News | Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Arbutus Biopharma Analyst Ratings
Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle
Arbutus Biopharma Reports FY24 EPS (38c), Consensus (55c)
Express News | Arbutus Biopharma Corp: Jury Trial in Moderna U.S. Mrna-Lnp Vaccine Litigation Scheduled for September 2025
Arbutus Biopharma | 10-K: FY2024 Annual Report
Arbutus Biopharma 2024 Rev $6.17M >ABUS
Arbutus Biopharma | 8-K: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Express News | Arbutus Biopharma Corp - Terminates Atm Program and Reduces Workforce by 57% in Q1 2025
Express News | Arbutus Biopharma Corp - Appoints Tuan Nguyen as CFO